Peregrine Capital Management LLC grew its position in Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 27.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 134,894 shares of the company’s stock after purchasing an additional 28,835 shares during the period. Peregrine Capital Management LLC’s holdings in Omnicell were worth $4,503,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Wellington Management Group LLP boosted its holdings in Omnicell by 156.4% during the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after purchasing an additional 1,265,818 shares during the last quarter. Millennium Management LLC bought a new position in shares of Omnicell during the 3rd quarter worth approximately $25,625,000. Boston Partners bought a new position in shares of Omnicell during the 4th quarter worth approximately $20,805,000. Two Sigma Investments LP boosted its stake in shares of Omnicell by 93.8% in the 3rd quarter. Two Sigma Investments LP now owns 559,969 shares of the company’s stock worth $17,051,000 after buying an additional 271,008 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Omnicell by 9.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock worth $71,985,000 after buying an additional 197,462 shares during the last quarter. 97.70% of the stock is owned by institutional investors.
Omnicell Stock Up 1.0%
Omnicell stock opened at $41.93 on Thursday. The firm has a 50 day moving average price of $41.48 and a 200-day moving average price of $41.52. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a twelve month low of $26.84 and a twelve month high of $55.00. The company has a market capitalization of $1.91 billion, a P/E ratio of 95.30, a P/E/G ratio of 1.07 and a beta of 0.96.
Insider Activity
In related news, EVP Nnamdi Njoku sold 3,090 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the sale, the executive vice president owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president owned 112,783 shares in the company, valued at $4,874,481.26. This represents a 4.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.92% of the company’s stock.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the company. Craig Hallum reaffirmed a “buy” rating and set a $55.00 price target on shares of Omnicell in a research report on Wednesday, April 29th. UBS Group set a $60.00 price objective on Omnicell and gave the stock a “buy” rating in a research report on Friday, March 13th. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Benchmark reaffirmed a “buy” rating on shares of Omnicell in a research report on Friday, March 13th. Finally, Weiss Ratings upgraded Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $59.86.
Omnicell Profile
Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.
Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.
Featured Stories
- Five stocks we like better than Omnicell
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL – Free Report).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
